Central Trust Company’s 10x Genomics TXG Stock Holding History

Central Trust Company’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-32	Closed	-$5K	–	1489
2021 Q4	$5K	Buy	+32	New	+$4.9K	﹤0.01%	1142

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Central Trust Company's TXG Position: Q1 2022 in Review

Central Trust Company sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 32 shares — an estimated $5K sold.

Central Trust Company first reported a position in TXG in Q4 2021 and held it in 1 quarter. The position peaked at $5K in Q4 2021. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

Central Trust Company reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
Central Trust Company sold 32 10x Genomics shares in Q1 2022, an estimated $5K.
Central Trust Company first reported a position in 10x Genomics in Q4 2021 and held it in 1 quarter.
Central Trust Company's 10x Genomics position peaked at $5K in Q4 2021.
314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on Central Trust Company's 13F filing for Q1 2022, filed 3 May 2022.